Bucillamine Induces the Synthesis of Vascular Endothelial Growth Factor Dose-Dependently in Systemic Sclerosis Fibroblasts via Nuclear Factor-κB and Simian Virus 40 Promoter Factor 1 Pathways

Molecular Pharmacology

Volumn 65, Issue 2, 2004, Pages 389-399

  Distler, Jörg H W ^a   Hagen, Claudia ^g   Hirth, Astrid ^a   Müller Ladner, Uif ^c   Lorenz, Hanns M ^b   Del Rosso, Angela ^d   Michel, Beat A ^a   Gay, Renate E ^a   Nanagara, Ratanavadee ^e   Nishioka, Kusuki ^f   Matucci Cerinic, Marco ^d   Kalden, Joachim R ^b   Gay, Steffen ^a   Distler, Oliver ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d UNIVERSITY OF FLORENCE   (Italy)

^e KHON KAEN UNIVERSITY   (Thailand)

^f ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

4,5,6,7 TETRAHYDRO 7,7 DIMETHYL 6 OXO 3H 1,2,5 DITHIAZEPINE 4 CARBOXYLIC ACID; BUCILLAMINE; CYSTEINE; DACTINOMYCIN; DRUG DERIVATIVE; DRUG METABOLITE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITHRAMYCIN; N (2 METHYL 2 METHYLTHIOPROPIONYL)CYSTEINE; PYRROLIDINE DITHIOCARBAMATE; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR A, HUMAN; VASCULOTROPIN; VASCULOTROPIN A;

ANGIOGENESIS; ARTICLE; BIOSYNTHESIS; CELL CULTURE; CONTROLLED STUDY; DERMIS; DOSE RESPONSE; DRUG EFFECT; FIBROBLAST; GEL MOBILITY SHIFT ASSAY; GENETICS; HUMAN; HUMAN TISSUE; IMMUNE SYSTEM; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; SIGNAL TRANSDUCTION; SIMIAN VIRUS 40; SYSTEMIC SCLEROSIS;

CELLS, CULTURED; CYSTEINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; HUMANS; NF-KAPPA B; PLICAMYCIN; RNA, MESSENGER; SCLERODERMA, SYSTEMIC; SIMIAN VIRUS 40; SP1 TRANSCRIPTION FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 9144259959     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.65.2.389     Document Type: Article

References (31)

1. Andrews NC and Faller DV (1991) A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 19:249919.
2. Blume SW, Snyder RC, Ray R, Thomas S, Koller CA, and Miller DM (1991) Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo. J Clin Investig 88:1613-1621.
3. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, et al. (1996) Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature (Lond) 380:435-439.
4. Distler O, del Rosso A, Giacomelli R, Cipriani P, Conforti ML, Guiducci S, Gay RE, Michel BA, Brühlmann P, Müller-Ladner U, et al. (2002a) Angiogenic and angiostatic factors in systemic sclerosis: Increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 4:R 11.
5. Distler O, Neidhart M, Gay RE, and Gay S (2002b) The molecular control of angiogenesis. Int Rev Immunol 21:33-49.
6. Distler O, Scheid A, Rethage J, del Rosso A, Guiducci S, Gay RE, Michel B, Müller-Ladner U, Matucci-Cerinic M, Gassmann M, et al. (2002c) Hypoxia-induced overexpression of vascular endothelial growth factor (VEGF) in systemic sclerosis (SSc) fails to induce angiogenesis in vivo. Arthritis Rheum 44:113.
7. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ, and Moore MW (1996) Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature (Lond) 380:439-442.
8. Finkenzeller G, Sparacio A, Technau A, Marme D, and Siemeister G (1997) Sp1 recognition sites in the proximal promoter of the human vascular endothelial growth factor gene are essential for platelet-derived growth factor-induced gene expression. Oncogene 15:669-676.
9. Finkenzeller G, Technau A, and Marme D (1995) Hypoxia-induced transcription of the vascular endothelial growth factor gene is independent of functional AP-1 transcription factor. Biochem Biophys Res Commun 208:432-439.
10. Hamm A, Krott N, Breibach I, Blindt R, and Bosserhoff AK (2002) Efficient transfection method for primary cells. Tissue Eng 8:235-245.
11. Hashimoto K and Lipsky PE (1993) Immunosuppression by the disease modifying antirheumatic drug bucillamine: inhibition of human T lymphocyte function by bucillamine and its metabolites. J Rheumatol 20:953-957.
12. Hayashi M, Matsunaga K, Okahara A, and Mita S (1991) Effect of bucillamine (SA96) on type 11 collagen induced arthritis in rats. J Rheumatol 18:691-695.
13. Hirohata S and Lipsky PE (1994) Comparative inhibitory effects of bucillamine and D-penicillamine on the function of human B cells and T cells. Arthritis Rheum 37:942-950.
14. Huang S, Pettaway CA, Uehara H, Bucana CD, and Fidler IJ (2001) Blockade of NF-kappa B activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion and metastasis. Oncogene 20:4188-4197.
15. Huang S, Robinson JB, Deguzman A, Bucana CD, and Fidler IJ (2000) Blockade of nuclear factor-kappa B signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res 60:5334-5339.
16. Ikeda E, Achen MG, Breier G, and Risau W (1995) Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 270:19761-19766.
17. Kim HA and Song YW (1997) A comparison between bucillamine and D-penicillamine in the treatment of rheumatoid arthritis. Rheumatol Int 17:5-9.
18. Ko HM, Seo KH, Han SJ, Ahn KY, Choi IH, Koh GY, Lee HK, Ra MS, and Im SY (2002) Nuclear factor kappa B dependency of platelet-activating factor-induced angiogenesis. Cancer Res 62:1809-1814.
19. Koyama S, Takagi H, Otani A, Oh H, Nishimura K, and Honda Y (2002) Inhibitory mechanism of vascular endothelial growth factor (VEGF) by bucillamine. Br J Pharmacol 137:901-909.
20. LeRoy EC (1996) Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am 22:675-694.
21. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, and Wollheim F (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202-205.
22. Matsuno H, Sugiyama E, Muraguchi A, Nezuka T, Kubo T, Matsuura K, and Tsuji H (1998) Pharmacological effects of SA96 (bucillamine) and its metabolites as immunomodulating drugs-the disulfide structure of SA-96 metabolites plays a critical role in the pharmacological action of the drug. Int J Immunopharmacol 20:295-304.
23. Matucci-Cerinic M, Generini S, and Pignone A (1997) New approaches to Raynaud's phenomenon. Curr Opin Rheumatol 9:544-556.
24. Mita S and Matsunaga K (1990) Differences in the effects of the antirheumatic drugs, bucillamine and D-penicillamine, on mitogen-induced proliferation of mouse spleen cells. Agents Actions 30:363-368.
25. Mukhopadhyay D, Knebelmann B, Cohen HT, Ananth S, and Sukhatme VP (1997) The von Hippel-Lindau tumor suppressor gene product interacts with Spl to repress vascular endothelial growth factor promoter activity. Mol Cell Biol 17:5629-5639.
26. Nagashima M, Yoshino S, Aono H, Takai M, and Sasano M (1999) Inhibitory effects of anti-rheumatic drugs on vascular endothelial growth factor in cultured rheumatoid synovial cells. Clin Exp Immunol 116:360-365.
27. Ryuto M, Ono M, Izumi H, Yoshida S, Weich HA, Kohno K, and Kuwano M (1996) Induction of vascular endothelial growth factor by tumor necrosis factor a in human glioma cells. Possible roles of SP-1. J Biol Chem 271:28220-28228.
28. Salimath B, Marine D, and Finkenzeller G (2000) Expression of the vascular endothelial growth factor gene is inhibited by p73. Oncogene 19:3470-3476.
29. Schreck R, Rieber P, and Baeuerle PA (1991) Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO (Eur Mol Biol Organ) J 10:2247-2258.
30. Varedi M, Ghahary A, Scott PG, and Tredget EE (1997) Cytoskeleton regulates expression of genes for transforming growth factor-beta 1 and extracellular matrix proteins in dermal fibroblasts. J Cell Physiol 172:192-199.
31. Yoshida S, Ono M, Shono T, Izumi H, Ishibashi T, Suzuki H, and Kuwano M (1997) Involvement of interleukin-8, vascular endothelial growth factor and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 17:4015-4023.